Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 2
Ce profil est validé par 2 label.

Company

LS CancerDiag

LS CancerDiag_logo
21
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

LS CancerDiag has developed DiagMMR®, a unique predictive diagnostic test to detect Lynch syndrome (LS). We provide easily interpretable and highly accurate results even before cancers develop, enabling preventive and personalized care.

Helsinki, Uusimaa, Finland

Send a message

  • 9

    employees

  • €10,000

    turnover

Anglais

LS CancerDiag

Anglais

LS CancerDiag is committed to reducing cancer mortality rates with a diagnostic method that detects an inherited cancer-causing condition prior to cancer.

DiagMMR® is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers. While current LS diagnosis relies on tumor studies, the quantitative DiagMMR® method allows carrier diagnosis based on a...

See more

LS CancerDiag is committed to reducing cancer mortality rates with a diagnostic method that detects an inherited cancer-causing condition prior to cancer.

DiagMMR® is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers. While current LS diagnosis relies on tumor studies, the quantitative DiagMMR® method allows carrier diagnosis based on a non-invasive tissue sample before the person has developed a cancer, without the knowledge and details of an inherited mutation.

  • 1

    Followers

  • 1

    Like

Our latest news

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1302 Entities
InvestHorizon - Accelerated
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.  This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
161 Entities

Communities

Access2EIC – Seal of Excellence
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
1871 Members
InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
1218 Members

Our history

Start in Aug 2013

  • Aug 2013

    LS CancerDiag is founded as a Spin-off from the University of Helsinki.

  • 2014-2018

    Patents filed and granted in all major markets (incl. EU, USA, China, Russia, Japan)

  • 2016

    LS CancerDiag joins Startup Health.

  • 2018

    Optimization and validation is completed.

  • 2019

    CE-mark obtained as IVD MD. Distribution agreements signed in Finland.

to be continued ...